Gene Therapy Breakthroughs for Cardiomyopathies: Insights into Tenaya’s Clinical Trials
Date: Wednesday, December 18th, 2024
6:00 – 7:00 PM ET*
Please join DCMF/GCAC for a webinar on Tenaya’s currently enrolling gene therapy trials.
Topics:
Dr. Whit Tingley, Tenaya’s Chief Medical Officer, will share updates on Tenaya’s MyPEAK-1 Study for HCM due to a MYBPC3 mutation and their RIDGE-1 Trial for ARVC due to a PKP2 mutation. Dr. Tingley will talk about how TN-201 and TN-401 are intended to work and discuss recently announced updates on the design and status of each clinical trial.
This will be an exciting webinar highlighting the advances of gene therapy for cardiomyopathies and the hope for the future.
Speakers:
Whit Tingley, M.D., Ph.D.
Chief Medical Officer, Tenaya Therapeutics
Dr. Tingley joined Tenaya as chief medical officer in December 2018. Previously, he served at Cytokinetics as vice president of clinical development, cardiology, and at Genentech as therapeutic area lead for cardiovascular and metabolism research and early development. Between 2009 and 2017, he held medical director and group medical director roles with increasing responsibility at Genentech and Roche. Whit formerly was adjunct associate professor of medicine in the cardiology division at the University of California, San Francisco (UCSF) and cared for patients as an attending cardiologist in the UCSF Cardiology Faculty Practice.
Dr. Tingley earned a B.A. degree from Brown University and his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He completed internship and residency programs at the Johns Hopkins Hospital, a cardiology fellowship at UCSF and post-doctoral research at the Gladstone Institutes.